摘要
目的研究多发性骨髓瘤（MM）患者骨髓单个核细胞中富半胱氨酸61（Cyr61）、血管内皮生长因子（VEGF）的表达情况，初步探讨Cyr61在MM发生、发展中的作用及其与VEGF基因的关系。方法采用实时荧光定量反转录-聚合酶链反应（RT—PCR）法对31例不同病程阶段MM患者及10例非肿瘤对照者骨髓单个核细胞中Cyr61和VEGFmRNA的表达进行检测。结果MM患者骨髓Cyr61和VEGF表达量（0．3652±1．5423，0．4815±1．3423）均高于对照组（0．1862±0．7542，0．2012±1．2331）（t值分别为2．352、2．403，均P〈0．05），Cyr61和VEGF的表达在Ⅰ期和Ⅱ期（0．2513±0．1365，0．3064±0．2124；0．3084±0．2254，0．3653±0．1265）之间差异无统计学意义（t值分别为1．782、1．824，均P〉0．05），而Ⅲ期患者Cyr61、VEGF表达（0．4632±0．1634，0．5356±0．2342）均较I期和Ⅱ期升高，差异均有统计学意义（t值分别为2．423、2．524，均P〈0．05），治疗前后Cyr61、VEGF表达量差异有统计学意义（t值分别为2．253、2．346、2．546、2．612，均P〈0．05）。MM患者Cyr61和VEGF的表达呈正相关（r=0．8941，P〈0．01）。结论Cyr61、VEGF的表达上调可能与MM的发生、发展、血管新生、疾病分期密切相关，两者可能通过共同的途径参与疾病的发生、发展过程。
Objective To investigate the expression of cystein rich 61 （Cyrrl） and vascular endothelial growth factor （VEGF） in different stages of multiple myeloma （MM） patients, evaluate their relationship with angiogenesis and prognosis, and to determine the relationship between Cyr61 and VEGF. Methods Expression of Cyrrl and VEGF in BMMNC from 31 patients with different stages of MM and 10 cases of control were detected by RT-PCR. Results Expression of Cyr61 and VEGF in patients with MM （0.3652＋1.5423, 0.4815±1.3423） were significantly elevated in comparison to control （0.1862＋0.7542, 0.2012±1.2331） （P 〈 0.05, P 〈 0.01）. Expression of Cyr61 and VEGF in stage UI （0.4632±0.1634, 0.5356± 0.2342） was signifieantly higher than those in stage I and stage 11 （t = 2.423, 2.524, P 〈 0.05）, but there was no difference between stage I and stage [I （0.2513±0.1365, 0.3064±0.2124; 0.3084±0.2254, 0.3653± 0.1265） （t = 1.782, 1.824, P 〉 0.05）. The levels of Cyr61 and VEGF were significantly decreased after chemotherapy eompared to before chemotherapy （P 〈 0.01）. Expression of Cyr61 and VEGF were positively correlated （r = 0.8941, P 〈 0.01）. Conclusion Cyr61 and VEGF may play roles in the angiogenesis and pathophysiology of MM. It can be used to guide treatment and estimate prognosis by monitoring Cyr61 and VEGF.
出处
《白血病．淋巴瘤》
CAS
2013年第8期487-490,共4页
Journal of Leukemia & Lymphoma
